Literature DB >> 1535824

Hormonal cytoreduction and radiotherapy for carcinoma of the prostate.

R J Shearer1, J H Davies, J S Gelister, D P Dearnaley.   

Abstract

We report the effect on prostatic volume of the administration of the luteinising hormone-releasing hormone (LHRH) analogue goserelin in 22 patients with locally advanced carcinoma of the prostate; 20 achieved a significant reduction in volume, the median volume being 66 ml before treatment (range 40-130) and 30 ml after 17 weeks (range 13-47). If used before external beam radiotherapy (RT), volume reduction will permit smaller boost fields and thus potentially reduce adverse radiotherapy effects. In addition, reducing tumour volume before RT may lead to an increase in local control. We discuss the possible role of hormonal volume reduction in the management of prostatic cancer.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1535824     DOI： 10.1111/j.1464-410x.1992.tb15601.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN： 0007-1331


  12 in total

1.  The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.

Authors:  C Onal; E Topkan; E Efe; M Yavuz; G Arslan; A Yavuz
Journal:  Br J Radiol       Date:  2009-07-06       Impact factor: 3.039

2.  Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study.

Authors:  Khairul Majumder; Yvonne Brandberg; Hemming Johansson; Enrique Castellanos; Anders Ullén; Bo Lennernäs; Sten Nilsson
Journal:  Mol Clin Oncol       Date:  2017-11-03

Review 3.  The efficacy of conventional external beam, three-dimensional conformal, intensity-modulated, particle beam radiation, and brachytherapy for localized prostate cancer.

Authors:  Tony Y Eng; Join Y Luh; Charles R Thomas
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 3.092

4.  The clinical impact of pathological review on selection the treatment modality for localized prostate cancer in candidates for brachytherapy monotherapy.

Authors:  Ryo Kishimoto; Takashi Saika; Kensuke Bekku; Hiroyuki Nose; Fernando Abarzua; Yasuyuki Kobayashi; Motoo Araki; Hiroyuki Yanai; Yasutomo Nasu; Hiromi Kumon
Journal:  World J Urol       Date:  2011-08-17       Impact factor: 4.226

Review 5.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.

Authors:  R N Brogden; D Faulds
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

Review 6.  Cancer of the prostate.

Authors:  D P Dearnaley
Journal:  BMJ       Date:  1994-03-19

7.  Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up.

Authors:  A Creak; E Hall; A Horwich; R Eeles; V Khoo; R Huddart; C Parker; C Griffin; M Bidmead; J Warrington; D Dearnaley
Journal:  Br J Cancer       Date:  2013-07-23       Impact factor: 7.640

8.  Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.

Authors:  Seungtaek Choi; Andrew K Lee
Journal:  Drug Healthc Patient Saf       Date:  2011-12-22

9.  Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer.

Authors:  C C Parker; A R Norman; R A Huddart; A Horwich; D P Dearnaley
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

10.  Induction of transforming growth factor beta in hormonally treated human prostate cancer.

Authors:  G H Muir; A Butta; R J Shearer; C Fisher; D P Dearnaley; K C Flanders; M B Sporn; A A Colletta
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.